This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck's Keytruda Gets Priority Review for Rare Skin Cancer
by Zacks Equity Research
Merck's (MRK) sBLA for Keytruda to expand its label for a rare form of skin cancer gets priority review from FDA.
Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events (revised)
by Zacks Equity Research
Novo Nordisk (NVO) announces post hoc results from SUSTAIN 6 study demonstrating that Ozempic consistently reduces the risk of major cardiovascular (CV) events across type II diabetes population.
AstraZeneca Up This Year So Far on Favorable Pipeline Updates
by Zacks Equity Research
AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
Merck (MRK) Receives FDA Approval for Two HIV Medicines
by Zacks Equity Research
Merck's (MRK) two new HIV-1 medicines, Delstrigo and Pifeltro, get approval in the United States.
Bristol-Myers' Sprycel Seeks Label Expansion in the U.S.
by Zacks Equity Research
The FDA accepts Bristol-Myers' (BMY) sBLA for label expansion of Sprycel for the treatment of pediatric patients with newly diagnosed Ph+ ALL.
Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus
by Zacks Equity Research
Novartis (NVS) & AbbVie (ABBV) get cancer approvals. Merck (MRK) gets FDA nod for two new HIV medicines.
4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline
by Kinjel Shah
We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
Esperion (ESPR) Combination Regimen Lowers Bad Cholesterol
by Zacks Equity Research
Esperion Therapeutics' (ESPR) combination regimen of bempedoic acid and Merck's Zetia achieves significant reduction in bad cholesterol in a phase III study.
Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events
by Zacks Equity Research
Novo Nordisk (NVO) announces post hoc results from SUSTAIN 6 study demonstrating that Ozempic consistently reduces the risk of major cardiovascular (CV) events across type II diabetes population.
AT&T Partners Softbox to Test Drones for Medicine Delivery
by Zacks Equity Research
AT&T's (T) trial run, if proven successful, is likely to pave the way for delivery of critical medicines during period of crisis.
Merck, Eisai Get EU Approval for Lenvima Label Expansion
by Zacks Equity Research
Merck (MRK) and Japanese partner Eisai gain an approval from the EU for Lenvima label expansion. The anti-cancer drug receives the regulatory body's nod for first-line treatment of unresectable HCC.
Bristol-Myers (BMY) sBLA for Empliciti Gets Priority Review
by Zacks Equity Research
The FDA granted priority review to the Bristol-Myers' (BMY) label expansion application for Empliciti seeking approval of the drug in combination with Pomalyst in multiple myeloma patients who are resistant to Revlimid.
Pharma Stock Roundup: FDA Blow for AGN, Label Expansion Nod for MRK, BMY Cancer Drugs
by Zacks Equity Research
Allergan (AGN) gets CRL for uterine fibroids candidate, Esmya. Merck (MRK) and Bristol-Myers' (BMY) PD-L1 inhibitors get FDA approval for expanded labels.
Horizon Pharma (HZNP) Boasts Robust Pipeline Amid Competition
by Zacks Equity Research
Horizon Pharma (HZNP) remains focused on advancing its pipeline candidates and is also making efforts to expand the label of its already approved drugs.
Japan Nods to AstraZeneca's Tagrisso for First-Line NSCLC
by Zacks Equity Research
AstraZeneca (AZN) receives approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the label expansion of Tagrisso.
Merck Gets FDA Nod for Keytruda Lung Cancer Label Expansion
by Zacks Equity Research
Merck (MRK) gets FDA approval to include overall survival data from a key late-stage lung cancer study, KEYNOTE-189 study, on the label of its PD-L1 inhibitor, Keytruda.
Bristol-Myers' Opdivo Gets FDA Nod for Small Cell Lung Cancer
by Zacks Equity Research
Bristol-Myers' (BMY) blockbuster immuno-oncology drug Opdivo gets the FDA approval for small cell lung cancer indication, which shall further expand the addressable patient population of the drug.
Merck, Eisai Get FDA Approval for Lenvima Label Expansion
by Zacks Equity Research
Merck (MRK) and Japanese partner Eisai gains an FDA approval for Lenvima label expansion. The anti-cancer drug receives the regulatory body's nod for the first line treatment of unresectable HCC.
Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication
by Zacks Equity Research
Bayer's (BAYRY) Monsanto subsidiary faces $289 million fine in Roundup lawsuit. Merck/Eisai's drug Lenvima gets FDA approval to treat the most common form of liver cancer.
Pain Therapeutics' Shares Rally on Alzheimer's Study Grant
by Zacks Equity Research
Pain Therapeutics (PTIE) receives grant of $3.2 million from National Institutes of Health to support development of its Alzheimer's disease candidate, PTI-125.
Agenus (AGEN) Delivering Well on Its Pipeline Candidates
by Zacks Equity Research
We have issued an updated report on Agenus (AGEN) highlighting updates on its pipeline candidates.
Here's Why Merck (MRK) Stock is Up Since Q2 Earnings Release
by Zacks Equity Research
Merck's (MRK) stock is up 4.2% since announcement of earnings in July. Let us have a look at the reasons for the same.
Agenus' (AGEN) Q2 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Agenus (AGEN) posts narrower-than-expected loss in the second quarter of 2018 and expects to file three investigational new drugs by the end of 2018.
Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus
by Zacks Equity Research
Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.
Top Research Reports with Q2 Earnings Analysis: Merck, CVS Health, CME Group & More
by Kalyan Nandy
Today's Research Daily features updated research reports on 16 major stocks, including Merck (MRK), CVS Health (CVS) and CME Group (CME).